An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis - Trial NCT06215638
Access comprehensive clinical trial information for NCT06215638 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Recruitment Completed. The study focuses on Rheumatoid Arthritis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
N/A
Mar 01, 2023
Dec 30, 2024
Primary Outcome
ACR20
Summary
The goal of this prospective single-arm open-label trial is to learn about efficacy and
 safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The
 main questions it aims to answer are:
 
 - Is Bortezomib an effective treatment option for patients with difficult-to-treat
 rheumatoid arthritis?
 
 - Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid
 arthritis?
 
 Participants will:
 
 - Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total.
 
 - Follow-up at weeks 4, 12, and 24, while biosamples will be collected.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06215638
Non-Device Trial